Showing posts with label Type 1 Diabetes. Show all posts

9/09/2026

Advances in Diabetes Care: Upgrading Insulin Pump Technology and Exploring New Therapies for Kidney Protection

Journal of Diabetes Investigation: Vol. 17, Issue 4 Summary

This issue highlights key advancements spanning both advanced diabetes technology and foundational pharmacology. Together, these studies emphasize the rapid evolution of modern diabetes management, showing how patient care is being optimized in real-world clinical practice and pointing toward future organ-protective strategies.

Advanced Diabetes Technology: Real-world evidence demonstrates that upgrading from the MiniMed™ 770G to the 780G hybrid closed-loop system significantly improves blood sugar stability, reduces night-time hypoglycemia, and eases diabetes-related anxiety in adults with Type 1 Diabetes.
Preventing Complications: Preclinical research shows that Calebin A, a natural compound, targets inflammation and cell damage pathways to protect kidneys from diabetic nephropathy.
Relevance to Care: These findings highlight the physical and psychological benefits of upgrading medical devices, while offering hope for novel, protective therapies that could shield patients from long-term diabetic complications.

Disclaimer The information presented in this article is provided for informational purposes only. The blog and its author assume no responsibility for the accuracy, safety, completeness, or reliability of the information. Any actions or decisions based on the information in this article are the sole responsibility of the reader.

This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.

Clinical Research & Technology

Effects of switching from MiniMed™ 770G to 780G on continuous glucose monitoring metrics and DTR-QOL scores: An observational study of Japanese people with type 1 diabetes mellitus

Authors: Eri Takagi, Junko Sato, Tatsuhiro Ayame, Shohei Fujikawa, Ryoki Mori, Haruna Yasuda, Azusa Ozaki, Haruki Nagashima, Mami Koshibu, Yuya Nishida, Fuki Ikeda, Hirotaka Watada

Research Objective:

To evaluate how switching from the MiniMed™ 770G insulin pump to the newer MiniMed™ 780G system affects blood sugar levels and quality of life (QOL) in Japanese adults with Type 1 Diabetes (T1D) over a one-year period.

Methods:

The researchers retrospectively analyzed continuous glucose monitoring (CGM) data from 36 adult patients over 48 weeks. They evaluated the time spent in the ideal blood sugar range (70–180 mg/dL), as well as high and low blood sugar levels. Additionally, they prospectively measured treatment-related quality of life (DTR-QOL) in 39 patients using standard questionnaires.

Main Findings:

Time in Range (70-180 mg/dL): Significantly increased from 71.6% to 76.1%.
High Blood Sugar: Time spent above 180 mg/dL decreased from 25.2% to 21.0%.
Hypoglycemia: While overall low blood sugar rates remained stable, nighttime low blood sugars (nocturnal hypoglycemia) dropped significantly from 4.9% to 2.7%.
A1C Levels: Average HbA1c improved from 7.2% to 7.0%.
Quality of Life: Patients reported significantly lower levels of diabetes-related anxiety and higher overall satisfaction with their treatment.

Clinical Significance:

This study provides the first one-year, real-world evidence of MiniMed™ 780G use in Japan. It demonstrates that the newer system's automated features translate directly to more stable blood sugars and happier, less anxious lives for patients.

Key Points for Patients & Families Upgrading from the MiniMed™ 770G to the 780G system can help keep your blood sugar in the healthy range longer and lower your HbA1c. Most notably, the 780G reduces the risk of dangerous blood sugar drops overnight and significantly eases daily diabetes stress and anxiety.

DOI: https://doi.org/10.1111/jdi.70257 (Read the original article)

Basic & Animal Research

Calebin A mitigates oxidative stress and inflammation in diabetic nephropathy via Nrf2/HO‐1 and NF‐κB signaling pathways

Authors: Reyhane Ghayour Vatanparast, Mahdieh Aliyari, Mahla Palizkaran Yazdi, Soodeh Alidadi, Mohammad Reza Sokhanvar, Sercan Karav, Prashant Kesharwani, Hossein Hosseini, Amirhossein Sahebkar

Research Objective:

To study the potential kidney-protecting (nephroprotective) properties and the underlying biological mechanisms of Calebin A, a natural compound related to turmeric, in treating diabetic nephropathy (kidney disease).

Methods:

Diabetic nephropathy was induced in mice. The mice were then treated with Calebin A, curcumin, or metformin for six weeks. Researchers examined their blood sugar, kidney function, signs of cell stress, inflammation, and physical scarring (fibrosis) in the kidney tissues.

Main Findings:

Kidney Protection: Calebin A treatment significantly improved blood sugar control and overall kidney performance.
Pathology Improvement: Tissue samples showed less physical damage and scarring in the kidneys of treated mice.
Cellular Mechanism: It successfully reduced harmful cell stress by boosting the body's natural antioxidant defense (Nrf2 pathway) and reduced swelling by blocking the inflammatory pathway (NF-κB pathway).

Clinical Significance:

These findings show that Calebin A holds strong potential as a multi-target natural therapy to protect kidneys from high blood sugar damage. However, because this was an animal study, further clinical trials are necessary to confirm if these protective effects work similarly in humans.

Key Points for Patients & Families Diabetic kidney disease is a serious complication caused by long-term high blood sugar. This promising laboratory study reveals that Calebin A (a natural compound) could serve as a future therapeutic option to help protect kidneys from swelling, scarring, and permanent damage.

DOI: https://doi.org/10.1111/jdi.70267 (Read the original article)

Diabetes Care Insights: Advancements in Neuropathy Detection, Automated Insulin Pumps, and Personalized Treatment Predictors

Journal of Diabetes Investigation: Vol. 17, Issue 2 Review

This issue highlights key advancements in managing diabetes and its complications, focusing on early detection methods, advanced treatment technologies, and personalized medical approaches. Neuropathy remains a core focus, with researchers identifying new, accessible, and objective ways to diagnose early nerve damage. Furthermore, we see how modern automated insulin pumps are significantly raising quality of life for those with type 1 diabetes, and how machine learning is helping clinicians predict which patients will benefit most from specific glucose-lowering therapies.

Key Takeaway: Future diabetes care is shifting towards highly customized treatment plans—utilizing technology and metabolic profiles to optimize patient outcomes.

Diabetic Neuropathy & Glycemic Swings

Impact of Glycemic Variability on Early Sweat Gland Dysfunction

Authors: Yang Ou, Xiao‐feng Hu, Zhi Liang, Xiao‐hui Zhang, Yi‐kun Zhou

Research Objective: To investigate how wide fluctuations in blood sugar (glycemic variability) affect sweat gland function in the hands and feet of patients with type 2 diabetes. Impaired sweat function (sudomotor dysfunction) is an early warning sign of diabetic peripheral nerve damage.

Methods: The researchers evaluated 206 patients with type 2 diabetes and 34 healthy individuals. Sweat function in the hands and feet was assessed using special conductivity tests. Diabetes patients also wore continuous glucose monitors (CGMs) to map out blood sugar fluctuations.

Main Findings: Patients with abnormal sweat function typically had diabetes for longer and suffered from wider blood sugar swings. Interestingly, a specific group of patients with "reversible" sweat gland damage showed high sensitivity to blood sugar control; keeping blood sugar levels steady between 5.0 and 10.0 mmol/L was linked with noticeable improvements in their sweat function.

Clinical Significance: Rapidly fluctuating blood sugar levels directly correlate with more severe nerve damage. Keeping blood sugar stable, specifically in the 5–10 mmol/L range, may protect and even restore early-stage nerve function.

Key point for patients: Avoiding dramatic peaks and valleys in your daily blood sugar, rather than just focusing on your average HbA1c, is crucial for preventing early nerve damage in your hands and feet.

DOI: https://doi.org/10.1111/jdi.70211

Diabetic Retinopathy & Genetics

Evaluating the Link Between White Blood Cell Counts and Diabetic Retinopathy

Authors: Yan Wang, Yunxian Gao, Zhiqiang Wang, Luhua Wu, Lixia Guo, Xiaoqiang Zhang, Jiaxin Wu, Shanshan Shang

Research Objective: To examine whether circulating white blood cells (leukocytes) play a direct, causal role in the development of diabetic retinopathy, a leading cause of vision loss.

Methods: The study used a sophisticated genetic comparison method called Mendelian randomization, drawing on data from large genomic studies of European populations to assess five types of white blood cells.

Main Findings: The genetic data showed that a higher count of a specific type of white blood cell, lymphocytes, is associated with a lower risk of developing diabetic retinopathy. Other cell types, such as neutrophils and monocytes, did not show a clear, robust causal relationship.

Clinical Significance: This study provides genetic evidence pointing toward the immune system's protective and active role in eye health, helping researchers narrow down specific inflammatory markers for future treatment targets.

Key point for patients: Your body's immune system and inflammatory responses are intricately linked with eye health. This research helps scientists understand how to protect blood vessels in the eye from diabetes-related damage.

DOI: https://doi.org/10.1111/jdi.70196

Clinical Trial Update

Phase IIa Evaluation of ONO-2910 for Diabetic Polyneuropathy

Authors: Yukiko Onishi, Takeshi Osonoi, Norio Takahashi, Toru Takiguchi, Eiichiro Morishima, Yoshimasa Aso, Kenji Sekiguchi, Hideki Kamiya, Jiro Nakamura

Research Objective: To evaluate the safety and clinical effectiveness of ONO-2910, a novel drug candidate designed to support nerve health by promoting helper-cell (Schwann cell) growth, in patients with diabetic polyneuropathy.

Methods: In a double-blinded clinical study, Japanese patients with type 2 diabetes and nerve pain/numbness were randomized to receive either 300 mg of ONO-2910 daily (76 patients) or a placebo (77 patients) for 12 weeks.

Main Findings: The drug was well-tolerated, with side effects being mild and similar to those who took the placebo (such as cold-like symptoms and mild diarrhea). However, after 12 weeks, there were no significant improvements in pain, numbness, or nerve impulse speeds compared to the placebo group.

Clinical Significance: While ONO-2910 has established a strong safety profile, a 12-week regimen did not show a therapeutic advantage over placebo for alleviating nerve symptoms. Future trials may need to explore different timelines or patient subgroups.

Key point for patients: Finding drugs to regenerate nerves remains a massive challenge. While this drug did not show improvement over placebo in this short study, it proved to be safe, opening doors for further investigations into neuropathy treatments.

DOI: https://doi.org/10.1111/jdi.70193

Personalized Medicine

Using Machine Learning to Predict Patient Response to Imeglimin

Authors: Katsuhiko Hagi, Kazumasa Yoshida, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki

Research Objective: To identify which patient-specific traits (like age, weight, and cholesterol levels) can predict a strong response to the diabetes medication imeglimin.

Methods: Researchers utilized machine learning algorithms to analyze data from three large clinical trials of imeglimin in Japan, looking at patients who took the drug on its own versus those who added it to existing insulin therapy.

Main Findings: For those taking imeglimin alone, nonsmokers with high baseline HbA1c (≥8.35%) and healthy LDL cholesterol levels achieved the greatest blood sugar drop. For patients taking it alongside insulin, older individuals with a lower BMI and lower liver enzymes (ALT) responded best.

Clinical Significance: This study demonstrates that advanced computing and artificial intelligence can help doctors "match" the right patient with the right medication, leading to better clinical success and highly personalized diabetes management.

Key point for patients: Not every diabetes drug works the same for everyone. In the future, your physician may use smart data tools to predict exactly how well a medication like imeglimin will work for you before you even start taking it.

DOI: https://doi.org/10.1111/jdi.70215

Lifestyle & COVID-19 Impact

How COVID-19 Containment Altered Body Composition in Adults with Diabetes

Authors: Yuko Yamaguchi, Yoshiyuki Hamamoto, Masahiro Imura, Yuichiro Yamada, Yutaka Seino

Research Objective: To observe how lifestyle restrictions, such as Japan's repeated COVID-19 states of emergency, influenced the body weight, muscle mass, and fat mass of people living with diabetes.

Methods: A retrospective study tracked 673 adults with diabetes across three periods: before the states of emergency, during them, and after they were lifted.

Main Findings: While patients' overall HbA1c (blood sugar average) remained remarkably stable, their physical body composition changed. All studied groups showed a continuous loss of skeletal muscle mass. Furthermore, older males experienced an increase in overall body fat percentage because their fat mass did not drop after restrictions ended, while their muscle continued to decline.

Clinical Significance: Prolonged periods of restricted physical activity can trigger "hidden" health risks like muscle loss (sarcopenia) and a rise in body fat percentage, even if your weight or laboratory blood sugar numbers appear stable.

Key point for patients: Staying active is about more than just managing your weight or blood sugar numbers. Protecting your muscles through resistance exercise is vital, especially for older men, during times when physical activity is restricted.

DOI: https://doi.org/10.1111/jdi.70197

Kidney Disease Research

Understanding the Role of PKM2 in Diabetic Kidney Disease and Cell Aging

Authors: Md. Imrul Kayes, Keizo Kanasaki

Research Objective: To review how changes in a specific enzyme called PKM2 (pyruvate kinase M2) affect kidney cell damage and aging (senescence) when exposed to chronic high blood sugar.

Methods: A detailed review of metabolic pathways, tracking how kidney cells process sugar under standard vs. hyperglycemic conditions.

Main Findings: Under long-term high blood sugar, the PKM2 enzyme shifts from its healthy, highly active form (tetramer) to a sluggish form (dimer). This sluggish form causes kidney cells to accumulate lactic acid and triggers cellular stress, inflammation, and cellular aging, which ultimately leads to kidney scarring and tissue damage.

Clinical Significance: Finding ways to stabilize PKM2 back into its healthy tetramer state could protect kidney cells from metabolic stress, offering a brand-new way to slow down or even reverse diabetic kidney disease (DKD).

Key point for patients: Scientists are looking deep inside our cells to find out why high blood sugar causes kidney wear-and-tear. Correcting how kidney cells burn sugar could prevent kidney damage in the future.

DOI: https://doi.org/10.1111/jdi.70231

Diabetes Technology

Upgrading to Advanced Insulin Pumps Improves Daily Treatment Satisfaction

Authors: Naoya Shimizu, Nozomi Ishimoto, Umeko Sakamoto, Mai Taneda, Akinori Hayashi, Takeshi Miyatsuka

Research Objective: To assess whether sequentially upgrading to more advanced, automated insulin pump systems truly increases patient satisfaction and improves overall blood sugar control in people with type 1 diabetes.

Methods: A retrospective study of patients with type 1 diabetes who upgraded from basic predictive low-glucose systems (MiniMed 640G) to early automated systems (770G), and finally to advanced hybrid closed-loop systems (780G). Satisfaction levels and glucose data were thoroughly compared.

Main Findings: While basic daily satisfaction scores remained relatively steady, patients reported a dramatic boost in overall comparative satisfaction after upgrading to the 780G advanced hybrid closed-loop pump. Along with feeling more satisfied, patients experienced lower HbA1c levels and spent more "time in range" (stable blood sugar ranges).

Clinical Significance: Newer "smart" insulin pump systems that automate correction doses do not just improve clinical metrics; they dramatically reduce the mental burden of diabetes, directly resulting in happier, more satisfied patients.

Key point for patients: If you are managing type 1 diabetes, upgrading to a modern "closed-loop" system (sometimes called an artificial pancreas) can give you better blood sugar control with significantly less daily hassle and stress.

DOI: https://doi.org/10.1111/jdi.70223

Innovative Diagnostics

Validating a Faster, Simpler Way to Diagnose Diabetic Nerve Damage

Authors: Tatsuhito Himeno, Hideki Kamiya, Yuka Shibata, Masato Kase, Hiromi Nakai‐Shimoda, Dai Yamagami, Masahiro Saito, Teruo Jojima, Aiko Arimura, Kenta Murotani, Chieko Suzuki, Hiroki Mizukami, Takahisa Deguchi, Yoshimasa Aso, Jiro Nakamura

Research Objective: To test if combining two rapid, simple tests—measuring minor variations in heart rate and using a quick hand-held nerve conduction device—can diagnose diabetic polyneuropathy (DPN) as accurately as complex, time-consuming hospital testing equipment.

Methods: A retrospective study of 314 patients compared results from classic, high-end electromyography machines against simple diagnostic tools: heart rate rhythm variation (CV_R-R) and a point-of-care nerve testing device (NC-stat/DPNCheck™).

Main Findings: Combining these two simple, quick tests provided diagnostic results that highly agreed with the older, complex, and expensive laboratory nerve conduction methods.

Clinical Significance: Objective nerve testing is vital because subjective symptoms do not always match actual physical nerve damage. Having a fast, reliable, and portable way to test nerves in ordinary clinics can help doctors spot and treat diabetic neuropathy years before it becomes severe.

Key point for patients: If you are concerned about nerve damage (numbness, pain, or tingling), ask your clinic about quick, portable nerve testing methods that do not require complex, uncomfortable hospital visits.

DOI: https://doi.org/10.1111/jdi.70190

New Discoveries in Diabetes: Uncovering Pathways, Risk Factors, and Personalized Care

Journal of Diabetes Investigation: Vol. 17, Issue 1 (2026)

Issue (JDI Vol.17, Issue1) Summary

This issue of the Journal of Diabetes Investigation presents a diverse collection of research, offering significant advancements across various facets of diabetes care and understanding. Key themes include uncovering fundamental mechanisms of type 1 diabetes progression, identifying age-specific differences in diabetic foot ulcers, exploring the broader benefits of SGLT2 inhibitors, and pinpointing novel risk markers for metabolic liver and cardiovascular disease in individuals with type 2 diabetes.

Particularly notable studies in this issue shed light on the intricate molecular pathways contributing to beta-cell loss in type 1 diabetes, potentially opening doors for new protective therapies. Another study highlights the critical need for age-tailored prevention and treatment strategies for diabetic foot ulcers, emphasizing that 'one size does not fit all' in managing this severe complication.

For patients and families, these findings offer insights into the complex nature of diabetes and its complications. The research underscores the importance of personalized care, from understanding individual risk factors for foot complications and liver disease to recognizing the wide-ranging benefits of existing medications like SGLT2 inhibitors. It also provides a glimpse into future therapeutic possibilities for preserving insulin-producing cells in type 1 diabetes.

Collectively, this issue’s papers have strong implications for future diabetes research and care, paving the way for more targeted interventions, improved risk assessment tools, and ultimately, enhanced quality of life for individuals living with diabetes.

Disclaimer

The information presented in this article is provided for informational purposes only. The blog and its author assume no responsibility for the accuracy, safety, completeness, or reliability of the information. Any actions or decisions based on the information in this article are the sole responsibility of the reader.

This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.

Individual Paper Reviews

Uncovering a Key Pathway in Type 1 Diabetes: PLAGL1 and Beta-Cell Destruction

Research Objective

This study aimed to understand how a gene called PLAGL1 contributes to the destruction of insulin-producing beta-cells in type 1 diabetes (T1DM), specifically investigating its role in oxidative stress, DNA damage, and inflammatory pathways.

Methods

Researchers used mouse beta-cells (NIT-1 line) to either increase or decrease PLAGL1 levels. They then measured DNA damage, oxidative stress markers, and indicators of beta-cell death. They also tested specific inhibitors for the cGAS/STING pathway, a known inflammatory response. Finally, they studied PLAGL1 overexpression in NOD mice (a model for T1DM) and observed the effects of cGAS/STING inhibition on glucose control and pancreatic beta-cell health.

Main Findings

The study found that increased PLAGL1 led to significant DNA damage in beta-cells, heightened oxidative stress, and impaired DNA repair. This resulted in the accumulation of damaged DNA, which activated an inflammatory pathway called cGAS/STING, ultimately causing beta-cell death and reduced insulin production. When this cGAS/STING pathway was blocked, beta-cell death was reduced, and insulin secretion improved in both cell cultures and diabetic mice. In mice, inhibiting this pathway also helped preserve beta-cell mass and improve blood sugar control.

Clinical Significance

This research identifies PLAGL1 as a key player in exacerbating beta-cell loss in type 1 diabetes by triggering a harmful cycle of oxidative DNA damage and inflammation. Targeting the cGAS/STING pathway offers a promising new therapeutic strategy to protect beta-cells and slow down the progression of T1DM.

Key Points for Patients

This study helps us understand more about why the body's own immune system attacks insulin-producing cells in type 1 diabetes. It suggests that future treatments might focus on blocking specific inflammatory pathways to protect these vital cells, potentially slowing down or even preventing the progression of type 1 diabetes.

DOI: https://doi.org/10.1111/jdi.70204

Diabetic Foot Ulcers: Clinical Characteristics Vary by Age

Research Objective

This study aimed to investigate how the clinical characteristics of diabetic foot ulcers (DFUs) differ among diabetic patients of various age groups.

Methods

Researchers conducted a retrospective study on 1,209 diabetic patients with foot ulcers. Patients were divided into young (<45 years), middle-aged (45-64 years), and elderly (≥65 years) groups. They analyzed patient data including diabetes duration, glycemic control, ulcer type, presence of other health conditions (comorbidities), ulcer healing rates during hospitalization, and all-cause mortality over a median follow-up of 44.5 months.

Main Findings

The study found that DFU characteristics are significantly age-dependent. Younger patients often had poorer blood sugar control, nerve-related (neuropathic) ulcers, and injuries due to mechanical stress. In contrast, older patients had more vascular complications (like peripheral artery disease) and ulcers that were a combination of nerve and circulation issues (neuro-ischemic). The prevalence of other health conditions like hypertension and kidney disease increased with age. Elderly patients also had significantly lower ulcer healing rates during hospitalization and higher mortality rates compared to younger and middle-aged groups.

Clinical Significance

These findings highlight that prevention and treatment strategies for diabetic foot ulcers need to be tailored to the patient's age. Understanding these age-related differences can lead to more effective, personalized care plans.

Key Points for Patients

If you have diabetes and a foot ulcer, it's important to know that your age can influence the type of ulcer you might have and how it heals. Younger individuals might face challenges with blood sugar control and nerve damage, while older individuals may have more circulation problems. Your healthcare team can use this information to create a more personalized plan for preventing and treating foot ulcers.

DOI: https://doi.org/10.1111/jdi.70181

SGLT2 Inhibitors Boost Hemoglobin Levels, Even with Chronic Inflammation

Research Objective

This study aimed to determine if chronic inflammation affects the ability of sodium-glucose co-transporter 2 inhibitors (SGLT2is) to increase hemoglobin levels in patients with diabetes.

Methods

A matched-pair cohort study was conducted with diabetic patients. New users of SGLT2is were compared to those who had never used them. Patients were grouped based on their levels of C-reactive protein (CRP), a marker of inflammation. Hemoglobin (Hb), CRP, and mean corpuscular volume (MCV) changes were tracked over time.

Main Findings

The study found that SGLT2 inhibitor use was associated with higher hemoglobin levels, regardless of whether patients had chronic inflammation or not. In fact, during the first six months, the increase in hemoglobin among SGLT2i users was even more noticeable in those with higher levels of inflammation. While hemoglobin increased, CRP levels remained stable, and MCV (red blood cell size) increased in SGLT2i users with higher CRP.

Clinical Significance

This research confirms that SGLT2 inhibitors can effectively increase hemoglobin levels in patients with diabetes, and this benefit is not diminished by the presence of chronic inflammation. This adds to the understanding of the broad positive effects of SGLT2is beyond blood sugar control.

Key Points for Patients

If you are taking an SGLT2 inhibitor for your diabetes, this study indicates that it can help improve your hemoglobin levels (a measure of red blood cells), which is beneficial for overall health. This positive effect appears to hold true even if you have ongoing inflammation in your body.

DOI: https://doi.org/10.1111/jdi.70189

Hormone Ratio Linked to Liver Disease Risk in Men with Type 2 Diabetes

Research Objective

This study aimed to explore the relationship between the ratio of estradiol to testosterone (E2/T ratio) and the risk of metabolic dysfunction-associated steatotic liver disease (MASLD), also known as fatty liver disease, in men with type 2 diabetes mellitus (T2DM).

Methods

This observational study included 1,441 male patients with type 2 diabetes. MASLD was diagnosed using abdominal ultrasonography. Researchers compared the clinical characteristics and prevalence of MASLD across different quartiles (four equal groups) of the E2/T ratio. Statistical methods, including binary logistic regression, were used to assess the association between the E2/T ratio and MASLD, adjusting for factors like age and diabetes duration.

Main Findings

The study found that as the E2/T ratio increased, the prevalence of MASLD significantly increased in men with type 2 diabetes (from 37.7% in the lowest quartile to 69.3% in the highest). After adjusting for other factors, a higher E2/T ratio was independently associated with an increased risk of MASLD. Additionally, patients with MASLD had higher levels of C-reactive protein (CRP), an inflammation marker, and CRP levels also increased with a higher E2/T ratio.

Clinical Significance

The E2/T ratio could serve as a simple and practical indicator to assess the risk of MASLD in men with type 2 diabetes. This association might be linked to the role of the E2/T ratio in inflammation, suggesting a potential pathway for intervention or risk stratification.

Key Points for Patients

For men with type 2 diabetes, the balance of certain hormones (estradiol and testosterone) might be an important clue to your risk for developing fatty liver disease (MASLD). A higher ratio of estradiol to testosterone was linked to a greater risk. Your doctor might consider checking this ratio as part of assessing your liver health and overall risk.

DOI: https://doi.org/10.1111/jdi.70202

Different Markers Predict Different Types of Early Heart Dysfunction

Research Objective

This study aimed to compare how two measures of insulin resistance—the triglyceride-glucose (TyG) index and the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)—relate to early, subtle signs of left ventricular (main pumping chamber of the heart) dysfunction in the general population.

Methods

The study recruited 2,850 participants with normal heart pumping function (ejection fraction ≥50%). They used an advanced ultrasound technique called speckle-tracking echocardiography to measure global longitudinal strain (GLS), which detects subtle changes in heart muscle contraction, and other indicators of heart function. Subclinical left ventricular systolic dysfunction (LVSD) was defined as GLS <18%.

Main Findings

Both higher TyG index and HOMA-IR were initially linked to reduced overall heart function. However, after accounting for other influencing factors, HOMA-IR was more strongly associated with subtle left ventricular systolic dysfunction (measured by GLS). In contrast, the TyG index showed a stronger relationship with early diastolic dysfunction, which is when the heart muscle has trouble relaxing and filling with blood properly (measured by the E/e' ratio). The study found that individuals with the highest HOMA-IR levels had more than double the odds of having subclinical LVSD, while the TyG index did not show a significant association with LVSD prevalence.

Clinical Significance

This research suggests that the TyG index and HOMA-IR might reflect different aspects of insulin resistance and its impact on heart function. HOMA-IR appears to be a better predictor for early issues with the heart's pumping ability (systolic dysfunction), while the TyG index is more closely related to problems with the heart's relaxation and filling (diastolic dysfunction). This distinction could help healthcare providers use these markers more effectively for early detection and risk assessment.

Key Points for Patients

If you have or are at risk for diabetes, your doctor might use different calculations (like the TyG index or HOMA-IR) to understand your insulin resistance. This study shows that these different measures might predict different types of early heart problems. For example, HOMA-IR might be better at detecting subtle issues with your heart's pumping strength, while the TyG index might be more useful for identifying early problems with how your heart relaxes and fills. This helps doctors get a more complete picture of your heart health.

DOI: https://doi.org/10.1111/jdi.70201

9/07/2026

New Horizons in Diabetes Care: Slowly Progressive T1D Guidelines, AI Kidney Prediction, and Precision Medicine Insights

Journal of Diabetes Investigation: Vol. 16, Issue 1 Summary

Welcome to the January 2025 review of the Journal of Diabetes Investigation. This issue highlights key advancements in personalizing diabetes management and predicting complications before they manifest. Major themes covered include official clinical practice guidelines for slowly progressive type 1 diabetes (SPIDDM), utilizing machine learning to catch early signs of kidney decline, and precision medicine approaches using specific blood biomarkers to determine individual diabetes risk.

Additionally, the issue delves into biological mechanisms behind common complications, such as impaired bone remodeling during orthodontic treatments in diabetic states, and genetic pathways delaying wound healing in diabetic foot ulcers. For patients and families, these studies emphasize a clear message: future diabetes care is becoming increasingly tailored, proactive, and focused on maintaining long-term organ and tissue health.

Clinical Practice Guidelines

Treatment Statement for Suspected Slowly Progressive Type 1 Diabetes (SPIDDM)

Research Objective: To provide clinical practice guidance on the management of patients with suspected ("probable") cases of slowly progressive type 1 diabetes (SPIDDM), distinguishing their treatment from "definite" cases.

Methods: A panel of expert medical specialists developed clinical recommendations based on the 2023 revised diagnostic criteria for SPIDDM, evaluating insulin therapies, non-insulin medications, and progressive monitoring strategies.

Main Findings: Patients diagnosed with "definite" SPIDDM should start insulin immediately. However, "probable" SPIDDM patients are in a non-insulin-dependent state, meaning their therapy can be more flexible. While early insulin can help protect remaining natural insulin-producing cells, it is not mandatory for all probable cases. Dipeptidyl peptidase-4 (DPP-4) inhibitors and biguanides (like metformin) are acceptable treatment alternatives, whereas sulfonylurea agents should be strictly avoided due to risks of accelerating pancreatic cell exhaustion. Close monitoring of natural insulin capacity is crucial.

Clinical Significance: This guideline aids physicians in tailoring therapy safely to protect the pancreas's natural insulin production without subjecting patients to unnecessarily early or rigid insulin regimens.

Key Points for Patients:

If you are diagnosed with "probable" slowly progressive type 1 diabetes, you do not necessarily have to start insulin right away. Your doctor may choose other safe medications to help preserve your body's natural insulin. Ensure you avoid sulfonylureas, and participate in regular checkups to monitor your pancreas function.

DOI: 10.1111/jdi.14267 | Read the original article

Precision Medicine & Risk Stratification

Customized Biomarker Strategy to Predict Type 2 Diabetes

Research Objective: To evaluate the predictive performance of a novel subgroup-specific biomarker strategy to identify individuals at high risk of developing type 2 diabetes.

Methods: A total of 1,287 non-diabetic adults from the Taiwan Lifestyle Cohort Study were followed from 2006 to 2019. Researchers analyzed multiple blood proteins, including VAP-1, SCG3, FGL1, ANGPTL6, and ANGPTL4, tracking who developed diabetes over a 6-year period.

Main Findings: About 12.2% of the participants developed diabetes during the follow-up. Elevated levels of Vascular Adhesion Protein-1 (VAP-1) in the blood were significantly associated with diabetes development. Most importantly, evaluating blood markers by dividing people into subgroups based on their gender and body mass index (BMI) dramatically improved the accuracy of diabetes prediction.

Clinical Significance: This subgroup-specific biomarker strategy supports early and precise preventive medicine, pointing doctors to the exact individuals who need early intervention to delay or avoid diabetes.

Key Points for Patients:

Predicting diabetes is no longer "one size fits all." In the future, a simple blood test tailored specifically to your gender and body weight category could pinpoint your exact risk level, giving you and your doctor a better chance to prevent the disease early.

DOI: 10.1111/jdi.14311 | Read the original article

Dental & Bone Remodeling

Why Diabetes Suppresses Tooth Movement During Orthodontic Care

Research Objective: To investigate how the diabetic state affects alveolar (jaw) bone remodeling and tooth movement when mechanical orthodontic force is applied.

Methods: Mechanical orthodontic loads were applied between molars in normal and diabetic mice. Researchers analyzed tooth movement rate, bone volume, bone-resorbing cells (osteoclasts), and genetic expression of bone-remodeling proteins.

Main Findings: Tooth movement was significantly delayed in diabetic mice. Bone-resorbing cells and bone remodeling activities were significantly lower in the diabetic group. This delay was directly linked to a drop in the expression of a key vascular growth factor (VEGF) and its activator protein (SP1) at the tooth-compression site.

Clinical Significance: The study uncovers the molecular mechanism (the SP1/VEGF pathway) behind delayed bone remodeling, helping explain why patients with diabetes might experience slower or altered results during orthodontic treatment like braces.

Key Points for Patients:

If you have diabetes and are planning to get braces or other orthodontic work, work closely with your dentist and endocrinologist. High blood sugar can slow down tooth movement by affecting jaw bone renewal, so maintaining stable blood sugar levels is vital for successful dental results.

DOI: 10.1111/jdi.14338 | Read the original article

Complication Science & Healing

Targeting Gene Signals to Accelerate Diabetic Foot Ulcer Healing

Research Objective: To explore how specific microRNAs and cellular proteins block wound healing in diabetic foot ulcers (DFU) and identify potential therapeutic targets.

Methods: An in vitro laboratory model of diabetic foot ulcers was built using human skin cells (keratinocytes) exposed to advanced glycation end products (AGEs). Cell growth, migration, and biological pathways were evaluated.

Main Findings: Elevated levels of a molecule called miR-155 were shown to delay cell growth and wound healing. Inhibiting miR-155 protected skin cells and helped them migrate to close wounds by regulating a chain of protective proteins, including HIF-1α, SOX2, and the EGFR/MEK/ERK pathway.

Clinical Significance: This laboratory discovery provides a clear roadmap of chemical pathways that could be targeted to develop advanced wound-healing creams or local therapies for diabetic ulcers.

Key Points for Patients:

Diabetic foot ulcers are difficult to heal, but scientists are uncovering the exact cellular "brakes" that prevent skin repair. By designing treatments that release these brakes, future medicine hopes to heal stubborn wounds much faster.

DOI: 10.1111/jdi.14327 | Read the original article

AI & Kidney Health

Machine Learning Predicts Kidney Decline Before Damage Occurs

Research Objective: To build a highly accurate machine learning model to identify patients with type 2 diabetes who are at risk of developing diabetic kidney disease.

Methods: Researchers utilized one year of historical time-series clinical data from type 2 diabetes patients, tracking and training AI models to predict when a patient's kidney function (eGFR) would drop below the milestone safety threshold of 60 mL/min/1.73m².

Main Findings: Traditional single-point tests are less reliable. The machine learning model achieved highly accurate predictions of future kidney decline by tracking fluctuating levels of urinary protein and eGFR over time, allowing detection while kidney function is still technically in a preserved, safe range.

Clinical Significance: This predictive software empowers physicians to intervene aggressively with therapies to protect kidneys before any permanent, serious stage of diabetic kidney disease develops.

Key Points for Patients:

Regular lab tests are valuable, but smart computer algorithms can now watch how your kidney numbers trend over a whole year. This allows your doctor to catch early signs of distress and adjust your medications before you notice any symptoms.

DOI: 10.1111/jdi.14309 | Read the original article

Intermittent Fasting, Kidney Biomarkers, and Islet Transplantation: Key Insights from the Journal of Diabetes Investigation

Journal of Diabetes Investigation: Volume 15, Issue 9 Summary

This issue of the Journal of Diabetes Investigation brings together vital advances in clinical management, early diagnostics, and advanced therapeutics for diabetes. The key research themes focus on practical lifestyle interventions, finding sensitive markers for diabetic kidney complications, and the real-world feasibility of cellular therapies.

Specifically, researchers explore the metabolic benefits of two different intermittent fasting protocols (16:8 vs. 14:10) for patients with obesity and type 2 diabetes. For diabetic kidney disease, new blood biomarkers have been identified that could help trace kidney injury early. Finally, an insightful review on pancreatic islet transplantation highlights how cell-based therapies can drastically improve the life quality of patients with severe type 1 diabetes.

Randomized Controlled Trial

Effect of intermittent fasting 16:8 and 14:10 compared with control‐group on weight reduction and metabolic outcomes in obesity with type 2 diabetes patients

Authors: Naparat Sukkriang, Supawan Buranapin

Research Objective: To evaluate and compare the impact of two intermittent fasting (IF) methods (16-hour fast/8-hour eat vs. 14-hour fast/10-hour eat) against a standard diet control group on weight loss and overall metabolic health in individuals with obesity and type 2 diabetes.

Methods: A randomized controlled trial was conducted with 99 participants who completed the study. Over 3 months, participants were assigned to three groups: the IF 16:8 protocol, the IF 14:10 protocol (both followed 3 days a week), or a normal diet control group.

Main Findings: Both intermittent fasting groups showed significant weight loss compared to the control group (which only lost an average of 0.55%). The IF 16:8 group experienced a 4.02% decrease in weight, whereas the IF 14:10 group achieved a 3.15% decrease. The IF 16:8 protocol was significantly more effective for weight loss than the 14:10 protocol. Additionally, both fasting groups experienced notable reductions in fasting blood sugar, HbA1c levels, and improved lipid (cholesterol and fat) profiles compared to controls.

Clinical Significance: Practicing intermittent fasting (either 16:8 or 14:10) just 3 days a week is an accessible and highly effective therapeutic strategy to manage weight, improve blood sugar control, and lower cardiovascular risk in obese type 2 diabetes patients.

Key Points for Patients:

Fasting for 14 or 16 hours on three selected days a week can help you lose weight and manage diabetes more effectively.
Fasting for 16 hours (16:8) appears to deliver better weight loss results than the 14-hour fast (14:10).
Both fasting approaches helped improve cholesterol levels and long-term blood sugar controls (HbA1c).

Original Article Link:
https://doi.org/10.1111/jdi.14186

Case-Control Study

Relationship between circulating thrombospondin‐1 messenger ribonucleic acid and microribonucleic acid‐194 levels in Chinese patients with type 2 diabetic kidney disease

Authors: Ning Ma, Weiwei Liu, Ning Xu, Dong Yin, Ping Zheng, Guofeng Wang, Yuan Hui, Jiping Zhang, Guanjun Han, Chuanhui Yang, Yan Lu, Xingbo Cheng

Research Objective: To investigate how the levels of certain genetic messengers in the blood (specifically circulating TSP-1 mRNA and miR-194) relate to the presence and severity of diabetic kidney disease (DKD).

Methods: This study analyzed 167 hospitalized patients with type 2 diabetes (divided into three groups based on urinary microalbumin, which indicates kidney function decline) and 163 healthy control subjects. Real-time laboratory analysis was used to measure circulating TSP-1 mRNA and miR-194.

Main Findings: Both markers (TSP-1 mRNA and miR-194) were significantly elevated in type 2 diabetes patients compared to healthy controls. TSP-1 mRNA levels climbed in step with rising levels of albumin in the urine. Statistical analyses showed that TSP-1 mRNA strongly correlated with clinical measures of kidney function (cystatin-c and microalbumin/creatinine ratio). Interestingly, miR-194 showed distinct variations across different stages of kidney damage, marking it as a potentially valuable screening molecule.

Clinical Significance: These molecular markers could act as early, non-invasive blood indicators to assess the presence and severity of kidney damage in diabetes patients, allowing doctors to detect complications before severe damage occurs.

Key Points for Patients:

Diabetic kidney disease is a common complication that requires early detection.
Scientists have found specific molecules (TSP-1 mRNA and miR-194) in the blood that correlate with early kidney strain.
In the future, simple blood tests tracking these molecules may help doctors monitor your kidney health more accurately without relying solely on standard urine samples.

Original Article Link:
https://doi.org/10.1111/jdi.14252

Review / Clinical Practice

Islet transplantation in Korea

Authors: Joonyub Lee, Kun‐Ho Yoon

Research Objective: To review the clinical implementation, success, and challenges of pancreatic islet transplantation as a cure-oriented treatment for severe Type 1 Diabetes in South Korea.

Methods: This review reports on islet transplantation outcomes performed at a key clinical center in Korea since 2013, highlighting two notable cases of allogenic islet transplantations.

Main Findings: Of the two patients who received transplantations, one achieved near-total insulin independence. The second patient, despite not reaching total insulin independence, had a dramatic reduction in life-threatening episodes of hypoglycemia (severe low blood sugar). These cases show that replacing lost islet cells is highly protective, even when complete insulin-free status is not fully maintained.

Clinical Significance: Islet transplantation represents an invaluable therapy to restore biological glucose control in patients with Type 1 Diabetes who suffer from unstable blood sugar levels and frequent, dangerous low-sugar episodes.

Key Points for Patients:

For type 1 diabetes, daily insulin injections do not always prevent sudden, dangerous blood sugar swings.
Islet transplantation is a procedure that transplants healthy, insulin-producing donor cells into the recipient's body.
This treatment can help some patients stop taking insulin entirely and highly reduces dangerous, unexpected drops in blood sugar.

Original Article Link:
https://doi.org/10.1111/jdi.14264

9/06/2026

Understanding Glycemic Variability, Autoimmune Diabetes Genetics, and Diabetic Kidney Disease Pathways

Journal of Diabetes Investigation: Vol. 15, Issue 1 Summary

This issue of the Journal of Diabetes Investigation brings together vital research focusing on the genetics, complications, and management tools of diabetes. The primary themes highlight how cutting-edge tools and genetic research can help personalize medicine and protect patients from long-term complications.

Key highlights include an exploration of the biological pathways behind diabetic kidney disease (nephropathy) and the identification of a genetic marker (the RPS26 gene) that could distinguish autoimmune types of diabetes (such as Type 1 and LADA) from Type 2 diabetes. Additionally, a comprehensive review of glycemic variability emphasizes the clinical value of Continuous Glucose Monitors (CGMs) in tracking blood sugar fluctuations to potentially prevent tissue damage.

For patients, families, and healthcare providers, these studies underscore a shift toward precision care—using advanced monitoring technology and genetic profiling to tailor treatments and mitigate complications before they progress.

Diabetic Nephropathy & Genetics

Identification and validation of voltage‐dependent anion channel 1‐related genes and immune cell infiltration in diabetic nephropathy

Authors: Jiaqun Lin, Mengjie Weng, Jing Zheng, Kun Nie, Siyi Rao, Yongjie Zhuo, Jianxin Wan

Research Objective:
To investigate the specific genes related to "voltage-dependent anion channel 1" (VDAC1) and analyze their connection with immune system activity (immune cell infiltration) in diabetic kidney disease (diabetic nephropathy).

Methods:
The researchers analyzed data from public gene expression databases of patients with diabetic nephropathy. They pinpointed key genes (hub genes) and analyzed their pathways. They then checked how these genes correlate with immune cells and validated their protein levels in laboratory models of diabetic mice (db/db mice). Finally, they searched for potential drugs that might target these genes to help slow down kidney damage.

Main Findings:
They discovered 57 VDAC1-related genes involved in major inflammatory and metabolic pathways (like PI3K, Notch, and TGF-β) in diabetic nephropathy. Specifically, five "hub" genes (ITGAM, B2M, LYZ, C3, and CASP1) were found to be highly active in the kidneys of diabetic mice and were strongly linked to the presence of immune cells.

Clinical Significance:
These findings show that immune system activation and specific cellular channels are deeply involved in diabetic kidney damage. Identifying these five hub genes provides prospective diagnostic markers and targets for developing new medications designed to protect the kidneys of patients with diabetes.

Key Points for Patients:
Researchers are mapping out the precise genetic and immune system changes that cause kidney damage in diabetes. Understanding these specific gene pathways is a major step toward creating target-specific drugs to prevent or treat diabetic kidney disease in the future.

DOI: https://doi.org/10.1111/jdi.14087
Read the original article →

Blood Sugar Dynamics & Technology

Glycemic variability: Measurement, target, impact on complications of diabetes and does it really matter?

Authors: Yifei Mo, Jingyi Lu, Jian Zhou

Research Objective:
To review how "glycemic variability" (blood sugar swings between extreme highs and lows) is measured, its targets, how it damages tissue, and its relationship with long-term diabetes complications.

Methods:
The authors summarized scientific literature from the past two decades, with a focus on Continuous Glucose Monitoring (CGM) devices, which track real-time sugar fluctuations. They evaluated clinical studies, biological tissue mechanisms, and population data.

Main Findings:
Continuous glucose monitoring provides a complete picture of sugar fluctuations that traditional HbA1c tests can miss. While many clinical studies link high glycemic variability to diabetes complications, especially in Type 2 diabetes, long-term clinical trials are still needed to clarify exactly how much blood sugar swings alone directly cause tissue damage.

Clinical Significance:
This review highlights glycemic variability as an important clinical metric alongside standard average blood sugar (HbA1c). It helps establish standards for how doctors assess blood sugar stability.

Key Points for Patients:
Keeping blood sugar steady is just as important as keeping your average numbers down. Rapid spikes and drops can stress your blood vessels. Using a Continuous Glucose Monitor (CGM) can help you see and manage these daily fluctuations.

DOI: https://doi.org/10.1111/jdi.14112
Read the original article →

Genetic Biomarkers & Diabetes Classification

Association of RPS26 gene polymorphism with different types of diabetes in Chinese individuals

Authors: Rong Song, Lingxiang Xie, Jin Ding, Yan Chen, Hailan Zou, Haipeng Pang, Yiman Peng, Ying Xia, Zhiguo Xie, Xia Li, Yang Xiao, Zhiguang Zhou, Jingyi Hu

Research Objective:
To determine if a specific genetic variation in the RPS26 gene (rs1131017) is linked to a higher risk of developing different types of diabetes (Type 1, LADA, or Type 2) in the Chinese Han population.

Methods:
The researchers examined the genetic information of 1,006 patients with Type 1 diabetes, 210 patients with LADA (Latent Autoimmune Diabetes in Adults), 642 patients with Type 2 diabetes, and 2,099 healthy control subjects. They also studied how this gene variation related to the patients' clinical features, like C-peptide levels (which show how much insulin the body produces).

Main Findings:
They found that a specific variation (carrying the "C allele") of the RPS26 gene significantly increases the risk of both Type 1 diabetes and LADA. Interestingly, this risk was not associated with Type 2 diabetes. Furthermore, patients with this gene variant produced less insulin (measured via lower postprandial or fasting C-peptide levels).

Clinical Significance:
The RPS26 gene variation serves as a clear genetic marker that distinguishes autoimmune types of diabetes (Type 1 and LADA) from non-autoimmune Type 2 diabetes. This genetic marker is directly linked to the body's impaired capacity to produce insulin.

Key Points for Patients:
Because different types of diabetes require different management strategies, getting an accurate diagnosis is critical. Discovering genetic markers like the RPS26 variant helps doctors identify and classify autoimmune forms of diabetes early, leading to more tailored and effective treatment plans.

DOI: https://doi.org/10.1111/jdi.14117
Read the original article →

Advances in Diabetes Care: Blood Sugar Stability, Safe Pregnancies, and Muscle Health

Issue Summary: Journal of Diabetes Investigation (Vol. 14, Issue 12)

In this monthly review, we highlight key scientific advancements focused on protecting the long-term well-being of individuals living with diabetes and prediabetes. The featured research from this issue centers on three essential pillars of modern diabetes care: stabilizing blood glucose variations to protect heart health, utilizing advanced medical devices to ensure safer pregnancies, and recognizing muscle preservation as an integral part of healthy aging.

Key Takeaways for Patients and Families: Maintaining stable blood sugar patterns (minimizing drastic daily or weekly swings) is crucial for preventing heart complications. Furthermore, modern technologies like continuous sensor-supported insulin pumps offer invaluable peace of mind and physical protection for pregnant mothers, while maintaining physical activity and monitoring muscle health remains highly protective against the frailty associated with aging.

Cardiovascular Health

Fluctuations in Blood Sugar Levels and Heart Risks in Asian Patients with Prediabetes and Type 2 Diabetes

Authors: Worapaka Manosroi, Mattabhorn Phimphilai, Nipawan Waisayanand, Supawan Buranapin, Chaicharn Deerochanawong, Siriluck Gunaparn, Arintaya Phrommintikul, Wanwarang Wongcharoen

Research Objective:

This study investigated how standard fluctuations in long-term blood sugar levels (known as HbA1c variability) affect the risk of serious heart issues in Asian patients diagnosed with prediabetes and type 2 diabetes.

Methods:

Researchers analyzed data from a large national registry in Thailand (the CORE-Thailand study) involving 3,811 participants. They tracked patients over an average of 4.5 years (54 months), categorizing them into four groups based on how widely their HbA1c levels fluctuated over time.

Main Findings:

Patients experiencing the highest fluctuations in blood sugar faced significantly higher health risks compared to those with stable levels. Specifically, those with highly volatile HbA1c values had a 2.77-fold increased risk of major cardiovascular events, an approximately 6.9-fold increased risk of heart attacks, and a 3.3-fold increased risk of hospitalization due to heart failure.

Clinical Significance:

While keeping overall average blood sugar low is important, keeping it stable and preventing spikes and drops is just as critical for protecting the heart. This highlights the need for consistent, steady glucose control in clinical practice.

Key Points for Patients:

Aim for steady, manageable daily habits rather than extreme adjustments that lead to dramatic fluctuations in your blood test results.
Speak with your doctor about tools or medication plans designed to smooth out your high and low glucose trends over time.

Original Article Link: Read the original article

Pregnancy Care

Benefits of Sensor-Augmented Insulin Pumps for Pregnant Women with Type 1 Diabetes

Authors: Hitomi Imafuku, Kenji Tanimura, Naohisa Masuko, Masako Tomimoto, Yutoku Shi, Akiko Uchida, Masashi Deguchi, Kazumichi Fujioka, Akane Yamamoto, Kei Yoshino, Yushi Hirota, Wataru Ogawa, Yoshito Terai

Research Objective:

This study evaluated whether using a sensor-augmented insulin pump (SAP)—which links an insulin pump with a continuous glucose sensor—improves pregnancy and newborn outcomes compared to standard insulin pump therapy paired with traditional finger-prick testing.

Methods:

Researchers compared two groups of pregnant women with type 1 diabetes: 40 women who used the advanced SAP system, and 29 women who used conventional insulin pumps with manual finger-prick monitoring.

Main Findings:

Mothers using the sensor-augmented pump (SAP) achieved healthier blood sugar levels during pregnancy. Strikingly, the rate of babies born "large for gestational age" (abnormally high birth weight, which can cause delivery complications) was significantly lower in the SAP group (27.5%) compared to the conventional group (65.5%). Other newborn health measures remained safe across both groups.

Clinical Significance:

Using sensor-linked insulin pump technology provides tighter, automated insights that directly support healthier fetal development and safer deliveries for mothers managing type 1 diabetes.

Key Points for Patients:

If you have type 1 diabetes and are planning a pregnancy or are currently pregnant, advanced insulin pump options could offer substantial protection for your baby's development.
Consult with your care team early to see if your insurance or clinic supports continuous glucose sensor integrations.

Original Article Link: Read the original article

Healthy Aging & Muscle Strength

How a Muscle Hormone Called "Musclin" Links to Preventing Muscle Weakness in Older Adults with Diabetes

Authors: Lei Fu, Qing Zhang, Juan Liu, Xiaoqing Yuan, Xinhua Ye

Research Objective:

Sarcopenia is the loss of muscle mass and physical strength that commonly affects older adults. This study looked at "musclin," a protein naturally produced by skeletal muscles during exercise, to see if its levels relate to muscle health in middle-aged and elderly patients with type 2 diabetes.

Methods:

Researchers examined 220 middle-aged and older Chinese adults with type 2 diabetes. They assessed their walking speed, handgrip strength, and total muscle mass using specialized body scans. Half of the participants (110) met the criteria for sarcopenia, while the other 110 served as a healthy comparison group.

Main Findings:

Patients with muscle weakness and loss (sarcopenia) had much lower levels of musclin in their blood than those with healthy muscles. The study showed that as blood musclin levels rose, the likelihood of having sarcopenia decreased significantly, proving musclin is an independent protective marker.

Clinical Significance:

Recognizing musclin's role may lead to new diagnostic markers or therapeutic options that help preserve physical strength and active lifestyles for individuals managing diabetes in their later years.

Key Points for Patients:

Protecting your muscle strength through light resistance exercises, stretching, or regular walking is an essential part of comprehensive diabetes management.
Since musclin is generated naturally through muscular activity, staying physically active is a great way to support your body's natural defenses against frailty.

Original Article Link: Read the original article